CEO’s View on experimental virus-based cancer treatments and the reality of bringing these cures to Market

April 9, 2015 4:08 PM

14 0

Brad Thompson, CEO of Oncolytics Biotech, discusses about virus-based immunotherapy treatments being tried in oncology like the one by Duke University that was based on engineering the polio virus. On March 29, 60 Minutes ran a two-segment profile of Duke University molecular biologist Matthias Gromeier, who engineered the polio virus so that it would kill glioblastoma cells while sparing healthy tissue.

The reality of actually getting cures to the market in the end according to Thompson is a daunting task and prone to failures.

Read more

To category page